Peter O Oluoch1,2, Cliff I Oduor2,3, Catherine S Forconi1, John M Ong'echa2, Christian Münz4, Dirk P Dittmer5, Jeffrey A Bailey3, Ann M Moormann1. 1. Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA. 2. Kenya Medical Research Institute/Center for Global Health Research, Kisumu, Kenya. 3. Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA. 4. Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland. 5. Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Abstract
BACKGROUND: Endemic Burkitt lymphoma (eBL) is associated with Epstein-Barr virus (EBV) and Plasmodium falciparum malaria coinfections. However, the role of Kaposi sarcoma-associated herpesvirus (KSHV), also endemic in Africa, has not been evaluated as a cofactor in eBL pathogenesis. METHODS: Multiplexed seroprofiles for EBV, malaria, and KSHV were generated for 266 eBL patients, 78 non-eBL cancers, and 202 healthy children. KSHV and EBV loads were quantified by PCR. RESULTS: KSHV seroprevalence did not differ by study group but was associated with age. Seropositivity, defined by K8.1/LANA or in combination with 5 other KSHV antigens (ORF59, ORF65, ORF61, ORF38, and K5) was associated with antimalarial antibody levels to AMA1 (odds ratio [OR], 2.41, P < .001; OR, 2.07, P < .001) and MSP1 (OR, 2.41, P = .0006; OR, 5.78, P < .001), respectively. KSHV loads did not correlate with antibody levels nor differ across groups but were significantly lower in children with detectable EBV viremia (P = .014). CONCLUSIONS: Although KSHV-EBV dual infection does not increase eBL risk, EBV appears to suppress reactivation of KSHV while malaria exposure is associated with KSHV infection and/or reactivation. Both EBV and malaria should, therefore, be considered as potential effect modifiers for KSHV-associated cancers in sub-Saharan Africa.
BACKGROUND: Endemic Burkitt lymphoma (eBL) is associated with Epstein-Barr virus (EBV) and Plasmodium falciparum malaria coinfections. However, the role of Kaposi sarcoma-associated herpesvirus (KSHV), also endemic in Africa, has not been evaluated as a cofactor in eBL pathogenesis. METHODS: Multiplexed seroprofiles for EBV, malaria, and KSHV were generated for 266 eBL patients, 78 non-eBL cancers, and 202 healthy children. KSHV and EBV loads were quantified by PCR. RESULTS:KSHV seroprevalence did not differ by study group but was associated with age. Seropositivity, defined by K8.1/LANA or in combination with 5 other KSHV antigens (ORF59, ORF65, ORF61, ORF38, and K5) was associated with antimalarial antibody levels to AMA1 (odds ratio [OR], 2.41, P < .001; OR, 2.07, P < .001) and MSP1 (OR, 2.41, P = .0006; OR, 5.78, P < .001), respectively. KSHV loads did not correlate with antibody levels nor differ across groups but were significantly lower in children with detectable EBVviremia (P = .014). CONCLUSIONS: Although KSHV-EBV dual infection does not increase eBL risk, EBV appears to suppress reactivation of KSHV while malaria exposure is associated with KSHV infection and/or reactivation. Both EBV and malaria should, therefore, be considered as potential effect modifiers for KSHV-associated cancers in sub-Saharan Africa.
Authors: Landon N Olp; Danielle M Shea; Maxine K White; Clement Gondwe; Chipepo Kankasa; Charles Wood Journal: Int J Cancer Date: 2012-08-20 Impact factor: 7.396
Authors: Ann M Moormann; Kiprotich Chelimo; Odada P Sumba; Mary L Lutzke; Robert Ploutz-Snyder; Duane Newton; James Kazura; Rosemary Rochford Journal: J Infect Dis Date: 2005-03-09 Impact factor: 5.226
Authors: G Miller; L Heston; E Grogan; L Gradoville; M Rigsby; R Sun; D Shedd; V M Kushnaryov; S Grossberg; Y Chang Journal: J Virol Date: 1997-01 Impact factor: 5.103
Authors: Gerald K K Cham; Louise Turner; John Lusingu; Lasse Vestergaard; Bruno P Mmbando; Jonathan D Kurtis; Anja T R Jensen; Ali Salanti; Thomas Lavstsen; Thor G Theander Journal: J Immunol Date: 2009-08-12 Impact factor: 5.422
Authors: Alison M Elliott; Denise Whitby; Robert Newton; Katie Wakeham; Emily L Webb; Ismail Sebina; Lawrence Muhangi; Wendell Miley; W Thomas Johnson; Juliet Ndibazza Journal: Infect Agent Cancer Date: 2011-09-30 Impact factor: 2.965
Authors: Eliana B Souto; Raquel da Ana; Vânia Vieira; Joana F Fangueiro; João Dias-Ferreira; Amanda Cano; Aleksandra Zielińska; Amélia M Silva; Rafał Staszewski; Jacek Karczewski Journal: Neoplasia Date: 2022-05-29 Impact factor: 6.218